SEARCH:   Advanced

Blood, 15 January 2008, Vol. 111, No. 2, pp. 964. This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ware, R. E. Search for Related Content PubMed Articles by Ware, R. E. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CORRESPONDENCE TCD response to hydroxyurea therapy Response: We thank the authors for summarizing the Belgian experience with transcranial doppler (TCD) for children with sickle cell disease (SCD). Although their data are retrospective, they describe significant differences in the TCD velocities of children treated with hydroxyurea compared with those who were not. Similar to our findings,1 children with highest baseline TCD velocities had the greatest treatment-related decreases. Their data also provide additional support for the use of hydroxyurea for primary and even secondary stroke prevention in children with SCD. We are encouraged that these pilot data further document the benefits of hydroxyurea for children with SCD, yet we maintain that treatment at the maximum tolerated dose is preferred.2 As we concluded in our paper, controlled multicenter prospective trials are needed to determine the efficacy of hydroxyurea therapy in these clinical settings.    Authorship Top Authorship References   Conflict-of-interest disclosure: The author declares no competing financial interests. Correspondence: Russell E. Ware, Department of Hematology, St Jude Children's Research Hospital, MS 355, 332 N Lauderdale Street, Memphis, TN 38105-2974; e-mail: russell.ware{at}stjude.org. Russell E. Ware    References Top Authorship References   Zimmerman SA, Schultz WH, Burgett B, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007; 110:1043–1047.[Abstract/Free Full Text] Zimmerman SA, Schultz WH, Davis DS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103:2039–2045.[Abstract/Free Full Text] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Use of hydroxyurea in prevention of stroke in children with sickle cell disease Nicolas Lefèvre, Dominique Dufour, Beatrice Gulbis, Phu-Quoc Lê, Catherine Heijmans, and Alina Ferster Blood 2008 111: 963-964. [Full Text] [PDF] Hydrolysis of extracellular ATP by CD39+ Treg cells: context matters! Markus Kleinewietfeld, Diletta DiMitri, Alexander Sternjak, Adamo Diamantini, Giovanna Borsellino, Luca Battistini, Olaf Rötzschke, and Kirsten Falk Blood 2008 111: 965-966. [Full Text] [PDF] Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia Sherri A. Zimmerman, William H. Schultz, Shelly Burgett, Nicole A. Mortier, and Russell E. Ware Blood 2007 110: 1043-1047. [Abstract] [Full Text] [PDF] This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ware, R. E. Search for Related Content PubMed Articles by Ware, R. E. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020